Efficacy and safety of lansoprazole combined with flupentixol-melitracen for functional dyspepsia: A randomized, double-blinded, placebo-controlled clinical trial

Figure 2 Percentage of treatment response and changes of estimated Leuven Postprandial Distress Scale scores over time between lansoprazole plus flupentixol-melitracen and placebo group. A and B: Percentage of clinical response and minimal clinical response at the end of treatment. The relative risk, along with its 95% confidence intervals, was calculated to compare the lansoprazole + flupentixol-melitracen group against the lansoprazole + placebo group; C and D: Over-time model-based estimated postprandial distress syndrome score and epigastric pain syndrome score changes. The gray shaded area represents the treatment period. ^aP < 0.05, and ^bP < 0.01. RR: Relative risk; CI: Confidence interval; PDS: Postprandial distress syndrome; EPS: Epigastric pain syndrome.